CONICET | Buscador de Institutos y Recursos Humanos

Immune checkpoint inhibitor treatment is a promising therapy as it proved effective in a subset of patients. It has been observed that a high number of non synonymous somatic mutations (NSM), also known as total mutational burden (TMB), correlates with a good response to checkpoint inhibitors in melanoma and lung. NSM can generate neoantigens, which, in turn, can be recognized by the immune system, triggering an anticancer immune response. While treating cancer with immunotherapy can be highly effective, only some patients respond to this treatment, so, there is a great interest to discriminate patients most likely to benefit from this therapy. The goal of that work is to provide the subset of genes or exons needed to be sequenced in order to predict the TMB.